Transscleral drug delivery for posterior segment disease.

Exciting new treatments are being developed for retinal degenerations and posterior segment eye disease. The successful treatment of these visually devastating diseases will likely require delivering effective doses of pharmacologic agents to the posterior segment, possibly in conjunction with surgical or genetic interventions. Currently, the treatment of diseases affecting the posterior segment is limited by the difficulty in delivering effective doses of drugs to target tissues in the posterior vitreous, retina or choroid. This review summarizes recent laboratory and clinical studies that indicate that transscleral delivery of therapeutic solutes might be an effective means of achieving therapeutic concentrations of these agents in the posterior eye.

[1]  M. Takada,et al.  Pluronic F-127 gels as a vehicle for topical administration of anticancer agents. , 1984, Chemical & pharmaceutical bulletin.

[2]  M. Prausnitz,et al.  The effect of intraocular pressure on human and rabbit scleral permeability. , 1999, Investigative ophthalmology & visual science.

[3]  J. V. van Meurs,et al.  Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. , 2000, Ophthalmology.

[4]  K Miyamoto,et al.  Transscleral delivery of bioactive protein to the choroid and retina. , 2000, Investigative ophthalmology & visual science.

[5]  J. Baum,et al.  Intraocular penetration of gentamicin after subconjunctibal and retrobulbar injection . , 1978, American journal of ophthalmology.

[6]  D. Maurice,et al.  Diffusion across the sclera. , 1977, Experimental eye research.

[7]  M. Prausnitz,et al.  Measurement and Prediction of Transient Transport across Sclera for Drug Delivery to the Eye , 1998 .

[8]  J. V. van Meurs,et al.  Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. , 1997, American journal of ophthalmology.

[9]  Jennifer I. Lim,et al.  Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. , 1995, Investigative ophthalmology & visual science.

[10]  M. Prausnitz,et al.  Fiber matrix model of sclera and corneal stroma for drug delivery to the eye , 1998 .

[11]  J. V. van Meurs,et al.  Dexamethasone concentration in vitreous and serum after oral administration. , 1998, American journal of ophthalmology.

[12]  M S Borcherding,et al.  Proteoglycans and collagen fibre organization in human corneoscleral tissue. , 1975, Experimental eye research.

[13]  J. Baum,et al.  Regional differences in ocular concentration of gentamicin after subconjunctival and retrobulbar injection in the rabbit. , 1977, American journal of ophthalmology.

[14]  M. Prausnitz,et al.  Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. , 1998, Journal of pharmaceutical sciences.

[15]  H F Edelhauser,et al.  Human sclera: thickness and surface area. , 1998, American journal of ophthalmology.

[16]  T. Maren,et al.  Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. , 1988, Archives of ophthalmology.

[17]  J. V. van Meurs,et al.  High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. , 1999, American journal of ophthalmology.

[18]  Ivana K. Kim,et al.  Diffusion of high molecular weight compounds through sclera. , 2000, Investigative ophthalmology & visual science.

[19]  T. F. Patton,et al.  Importance of the noncorneal absorption route in topical ophthalmic drug delivery. , 1985, Investigative ophthalmology & visual science.

[20]  I. Kwon,et al.  Development of a local antibiotic delivery system using fibrin glue , 1996 .

[21]  A. Bill.  MOVEMENT OF ALBUMIN AND DEXTRAN THROUGH THE SCLERA. , 1965, Archives of ophthalmology.

[22]  J. Lang.  Ocular drug delivery conventional ocular formulations , 1995 .